Mosunetuzumab Consolidation Treatment for Older Patients with Diffuse Large B-Cell Lymphoma Detecting Circulating Tumor DNA After Pola-R-mini-CHP Chemotherapy

What this Trial Is About

Researchers are studying older patients with diffuse large B-cell lymphoma DLBCL to understand how to better control the disease and reduce treatment side effects. The study focuses on patients aged 70 and older who have completed initial treatment with polatuzumab vedotin, rituximab, and dose-attenuated CHP chemotherapy. It aims to identify patients who still have small amounts of lymphoma DNA circulating tumor DNA or ctDNA in their blood after treatment and evaluate if giving an additional therapy can improve outcomes. The study also assesses the safety of this approach and its effect on patients physical function using a geriatric assessment tool. Patients who show a complete response on imaging but still have detectable ctDNA will receive six cycles of mosunetuzumab, a bispecific antibody, given intravenously with a specific dosing schedule over 18 weeks. Those with no detectable ctDNA after initial therapy will be observed without additional treatment. Patients with partial response will be managed according to study guidelines. The study uses a device called ClonoSEQ to detect ctDNA in the blood. Participants will undergo regular evaluations including blood tests to measure ctDNA levels, imaging scans, and functional assessments. The main outcome measured is the rate at which ctDNA clears from the blood after mosunetuzumab treatment. Secondary outcomes include response rates to the initial chemotherapy. The study monitors safety and tolerability throughout. Participation lasts through the treatment and observation periods, with assessments scheduled to track disease control and patient health.

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP